Drug Trial Radar · NCT03191799
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
195
Actual
Start
Sep 5, 2017
Primary completion
Nov 19, 2020
Study completion Nov 19, 2020
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected to be enrolled at approximately 85 sites globally. Participants will receive an initial weekly dose of prophylactic emicizumab subcutaneously for 4 weeks, followed by a weekly maintenance dose subcutaneously for the remainder of the 2-year treatment period.
Conditions
- Hemophilia A
Interventions
EmicizumabDrug
Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading ScaleTime frame: From Baseline until study completion (up to 2 years)
- Adverse Events (AEs) Rates Per 100 Patient-Years for All-Grade AEs, Serious AEs, and Grade ≥3 AEsTime frame: From Baseline until study completion (up to 2 years)
- Number of Participants by Hematology and Biochemistry Laboratory Parameter Test Results as Shifts From the WHO Toxicity Grade at Baseline to the Worst WHO Toxicity Grade Post-BaselineTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
- Change From Baseline in Body Temperature at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
- Change From Baseline in Systolic Blood Pressure at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
- Change From Baseline in Diastolic Blood Pressure at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
- Change From Baseline in Pulse Rate at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
- Change From Baseline in Respiratory Rate at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
- Change From Baseline in Body Weight at Specified TimepointsTime frame: Baseline, Weeks 2, 3, and 5; Months 3, 6, 9, 12, and 18; and at Early Termination/Study Completion (up to 24 months)
Locations
72 sites in 24 countries. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital; Haematology
Camperdown, New South Wales, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
UZ Leuven Gasthuisberg
Leuven, Belgium
Centro de Hematologia E Hemoterapia Do Parana - Hemepar
Curitiba, Paraná, Brazil
Instituto Estadual de Hema
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital das Clinicas - UNICAMP
Campinas, São Paulo, Brazil
Faculdade de Medicina de Ribeirão Preto - Universidade de Sao Paulo
Ribeirão Preto, São Paulo, Brazil
Kaye Edmonton Clinic
Edmonton, Alberta, Canada
CancerCare Manitoba; Neuro-Oncology
Winnipeg, Manitoba, Canada
McMaster University Health Sciences Center
Hamilton, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Centro de Atención e Investigación Médica CAIMED S.A.S
Localidad Puente Aranda, Colombia
Hospital Pablo Tobon Uribe
Medellín, Colombia
Helsingin yliopistollinen keskussairaala, Meilahden sairaala
Helsinki, Finland
Vivantes Klinikum im Friedrichshain - Landsberger Allee, Angiologie und Hämostaseologie
Berlin, Germany
Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin
Bonn, Germany
Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin; Johann Wolfgang Goethe-Univers.
Frankfurt/M., Germany
Universitätsklinikum Leipzig, Innere Medizin, Neurologie, Dermatologie; Zentrum für Hämostaseologie
Leipzig, Germany
Hämophilie-Zentrum Rhein Main GmbH
Mörfelden-Walldorf, Germany
Klinikum der Universität München, Campus Innenstadt; Hämostaseologische Ambulanz/Hämophiliezentrum
München, Germany
Oncomedica
Guatemala City, Guatemala
Magyar Honvédség Egészségügyi Központ; Országos Haemophilia Központ
Budapest, Hungary
Országos Vérellátó Szolgálat - Győri Regionális Vérellátó Központ
Győr, Hungary
University of Pecs, I st Dept of Internal Medicine
Pécs, Hungary
Grant Medical Foundation, Ruby Hall Clinic
Pune, India
St. John's Medical College & Hospital; Department of Medicine
Bengaluru, Karnataka, India
King Edward Memorial Hospital and Seth G.S. Medical College; Department of Hematology
Mumbai, Maharashtra, India
Fortis Hospitals Limited
Mumbai, Maharashtra, India
Sahyadri Speciality Hospital; Hematology & Bone Marrow Unit
Pune, Maharashtra, India
Christian Medical College & Hospital; Department of Haematology
Vellore, Maharashtra, India
Nil Ratan Sircar Medical College and Hospital; Department of Hematology
Kolkata, West Bengal, India
Sheba Medical Center - National Hemophilia Center
Tel HaShomer, Israel
AOU Federico II; Medicina Clinica Chirurgia Centro Emocoaugulopatie e Emofilia
Naples, Campania, Italy
AOU Policlinico S. Orsola Malpighi; U.O. Angiologia e Malattie della Coagulazione Marino Golinelli
Bologna, Emilia-Romagna, Italy
AOU di Parma; Dip Emergenza-Urgenza Centro Riferimento Regionale per l'emofilia
Parma, Emilia-Romagna, Italy
Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol
Rome, Lazio, Italy
IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
Milan, Lombardy, Italy
AO Città Salute e Scienza D-Osp S. G. Battista Molinette; SSCVD Malattie Tromboti e Emorragiche
Turin, Piedmont, Italy
Azienda Uni Ria Policlinico P. Giaccone ; Divisione Di Ematologia E Trapianto
Palermo, Sicily, Italy
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.